Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 12Phase 3 5Phase 1/2 2Phase EARLY_PHASE1 1

Status

Terminated 5Unknown 2Completed 2Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × rucaparib × Clear all
NCT04209595 2025-03-17

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
10 enrolled 13 charts
Thoracic

Small Cell Lung Carcinoma

NCT01482715 2023-06-09

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

pharmaand GmbH

Phase 1/2 Completed
136 enrolled 30 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡